CV6 Therapeutics is a pioneering biotech company headquartered in Belfast, Northern Ireland, dedicated to disrupting the cornerstone therapy markets in oncology and inflammatory diseases.
At CV6 Therapeutics, our mission is to disrupt cornerstone therapies with innovative solutions in oncology and inflammatory diseases, transforming patient care in these large high-impact markets through cutting edge science.
CV6 Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168 Belfast, UK, 15 August 2024 – CV6 Therapeutics (NI) Ltd. (“CV6”), a clinical-stage pharmaceutical company dedicated to improving the lives of patients with cancer and inflammatory diseases by developing novel, first-in-class, small molecules targeting Uracil-DNA […]
Find Out More